Health> Vol.6 No.8, March 2014

Immunoglobulin: A Natural Way to Suppress Helicobacter pylori in Humans

DownloadDownload as PDF (Size:1809KB)  HTML    PP. 781-791  

ABSTRACT

The use of immunoglobulin is successfully applied in different areas of research, diagnostics, medical application and biotechnology. Egg yolk immunoglobulin (IgY) can successfully compete with immunoglobulin (IgG) produced in the blood of mammals. Recently, successful progresses have been achieved in Japan through industrialization of IgY technology. Using IgY has been shown to provide a safer, more efficient and less expensive method for managing disease-causing pathogens. Helicobacter pylori (H. pylori), a spiral Gram-negative microaerophilic pathogen, it infects over 50% of the population worldwide, and is recognized as the etiologic agent of gastritis, peptic ulcer, and has been linked to the development of gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. It is found that urease is the most abundant protein of H. pylori. Urease is recognized as an essential factor in the organism colonization of the gastric mucosa. The eradication of H. pylori by administration of oral antimicrobials is not always successful and may be associated with adverse effects. Therefore, several treatment regimens have emerged to cure H. pylori infection. Accordingly, a novel approach in prevention and reduction of H. pylori infection has been reported based on production of urease-specific immunoglobulin that can suppress the bacterial colonization through urease-binding by anti-H. pylori urease IgY (IgY-urease). The use of IgY against a pathogenic factor of H. pylori will be a prudent way to suppress the infection.

Cite this paper

Abdou, A. , Ahmed, M. , Yamashita, Y. and Kim, M. (2014) Immunoglobulin: A Natural Way to Suppress Helicobacter pylori in Humans. Health, 6, 781-791. doi: 10.4236/health.2014.68100.

References

[1] Blaser, M.J. (2006) Who Are We? Indigenous Microbes and the Ecology of Human Diseases. EMBO Reports, 7, 956-960.
http://dx.doi.org/10.1038/sj.embor.7400812
[2] Bytzer, P., Dahlerup, J.F., Eriksen, J.R., Jarbøl, D.E., Rosenstock, S. and Wildt, S. (2011) Diagnosis and Treatment of Helicobacter pylori Infection. Danish Medical Bulletin, 58, C4271.
[3] Butcher, G.P. (2003) Gastroenterology: An Illustrated Colour Text 2003. Elsevier Health Sciences.
[4] Ryan, Kenneth. (2010) Sherris Medical Microbiology 2010. McGraw-Hill, Boston, 573, 576.
[5] Kusters, J.G., van Vliet, A.H. and Kuipers, E.J. (2006) Pathogenesis of Helicobacter pylori Infection. Clinical Microbiology Reviews, 19, 449-490.
http://dx.doi.org/10.1128/CMR.00054-05
[6] Suerbaum, S. and Michetti, P. (2002) Helicobacter pylori Infection. The New England Journal of Medicine, 347, 1175-1186.
http://dx.doi.org/10.1056/NEJMra020542
[7] Selgrad, M. and Malfertheiner, P. (2008) New Strategies for Helicobacter pylori Eradication. Current Opinion in Pharmacology, 8, 593-597.
http://dx.doi.org/10.1016/j.coph.2008.04.010
[8] Carson, C.F. and Riley, T.V. (2003) Non-Antibiotic Therapies for Infectious Diseases. Communicable Diseases Intelligence, 27, S143-S146.
[9] Suzuki, H., Nomura, S., Masaoka, T., Goshima, H., Kamata, N., Kodama, Y., Ishii, H., Kitajima, M., Nomoto, K. and Hibi, T. (2004) Effect of Dietary Anti-Helicobacter pylori-Urease Immunoglobulin Y on Helicobacter pylori Infection. Alimentary Pharmacology & Therapeutics, 20, 185-192.
http://dx.doi.org/10.1111/j.1365-2036.2004.02027.x
[10] Shin, J.H., Nam, S.W., Kim, J.T., Yoon, J.B., Bang, W.G. and Roe, I.H. (2003) Identification of Immunodominant Helicobacter pylori Proteins with Reactivity to H. pylori-Specific Egg-Yolk Immunoglobulin. Journal of Medical Microbiology, 52, 217-222.
http://dx.doi.org/10.1099/jmm.0.04978-0
[11] Shin, J.H., Roe, I.H. and Kim, H.G. (2004) Production of Anti-Helicobacter pylori Urease-Specific Immunoglobulin in Egg Yolk Using an Antigenic Epitope of H. pylori Urease. J Journal of Medical Microbiology, 53, 31-34.
http://dx.doi.org/10.1099/jmm.0.05327-0
[12] Nomura, S., Suzuki, H., Masaoka, T., Kurabayashi, K., Ishii, H., Kitajima, M., Nomoto, K. and Hibi, T. (2005) Effect of Dietary Anti-Urease Immunoglobulin Y on Helicobacter pylori Infection in Mongoliangerbils. Helicobacter, 10, 43-52.
http://dx.doi.org/10.1111/j.1523-5378.2005.00290.x
[13] Horie, K., Horie, N., Abdou, A.M., Yang, J.O., Yun, S.S., Chun, H.N., Park, C.K., Kim, M. and Hatta, H. (2004) Egg Yolk Immunoglobulin (IgY) on Helicobacter pylori in Humans. Journal of Dairy Science, 87, 4073-4079.
http://dx.doi.org/10.3168/jds.S0022-0302(04)73549-3
[14] Suzuki, M., Maruyama, K., Suzuki, H., Tanaki, S., Suzuki, K. and Ishii, H. (2004) 13C-Ethanol Breath Test Reveals Impaired Alcohol Metabolism in Patients with Helicobacter pylori Infection. Alimentary Pharmacology & Therapeutics, 20, 109-115.
http://dx.doi.org/10.1111/j.1365-2036.2004.02020.x
[15] Parsonnet, J., Blaser, M.J., Perez-Perez, G.I., et al. (1992) Symptoms and Risk Factors of Helicobacter pylori Infection in a Cohort of Epidemiologists. Gastroenterology, 102, 41-46.
[16] Cullen, D.J., Collins, B.J., Christiansen, K.J., et al. (1993) When Is Helicobacter pylori Infection Acquired? Gut, 34, 1681-1682.
http://dx.doi.org/10.1136/gut.34.12.1681
[17] Sipponen, P., Kosunen, T.U, Samloff, I.M., et al. (1996) Rate of Helicobacter pylori Acquisition among Finnish Adults: A Fifteen Year Follow-Up. Scandinavian Journal of Gastroenterology, 31, 229-232.
http://dx.doi.org/10.3109/00365529609004871
[18] Malaty, H.M., Evans, D.G., Evans, Jr., D.J. and Graham, D.Y. (1992) Helicobacter pylori in Hispanics: Comparison with Blacks and Whites of Similar Age and Socioeconomic Class. Gastroenterology, 103, 813-816.
[19] Malaty, H.M. and Graham, D.Y. (1994) Importance of Childhood Socioeconomic Status on the Current Prevalence of Helicobacter pylori Infection. Gut, 35, 742-745.
http://dx.doi.org/10.1136/gut.35.6.742
[20] Kosunen, T.U., Aromaa, A., Knekt, P., et al. (1997) Helicobacter Antibodies in 1973 and 1994 in the Adult Population of Vammala, Finland. Epidemiology & Infection, 119, 29-34.
http://dx.doi.org/10.1017/S0950268897007565
[21] Tone, M.A. (1999) Transmission of Helicobacter pylori. Postgraduate Medical Journal, 75, 198-200.
[22] Everhart, J.E. (2000) Recent Developments in the Epidemiology of Helicobacter pylori. Gastroenterology Clinics of North America, 29, 559-578.
http://dx.doi.org/10.1016/S0889-8553(05)70130-8
[23] Gasbarrini, A., Anti, M., Franceschi, F., Armuzzi, A., Cotichini, R., Ojetti, V., Candelli, M., Lippi, M.E., Paolucci, M., Cicconi, V., Cammarota, G., Danese, S., Silveri, N.G., Catananti, C., Pola, P., Stroffolini, T. and Gasbarrini, G. (2001) Prevalence of and Risk Factors for Helicobacter pylori Infection among Healthcare Workers at a Teaching Hospital in Rome: The Catholic University Epidemiological Study. European Journal of Gastroenterology & Hepatology, 13, 185-189.
http://dx.doi.org/10.1097/00042737-200102000-00015
[24] Eaton, K.A., Suerbaum, S., Josenhans, C. and Krakowka, S. (1996) Colonization of Gnotobiotic Piglets by Helicobacter pylori Deficient in Two Flagellin Genes. Infection and Immunity, 64, 2445-2448.
[25] Rektorschek, M., Weeks, D., Sachs, G. and Melchers, K. (1998) Influence of pH on Metabolism and Urease Activity of Helicobacter pylori. Gastroenterology, 115, 628-641.
http://dx.doi.org/10.1016/S0016-5085(98)70142-8
[26] Segal, E.D., Falkow, S. and Tompkins, L.S. (1996) Helicobacter pylori Attachment to Gastric Cells Induces Cytoskeletal Rearrangements and Tyrosine Phosphorylation of Host Cell Proteins. Proceedings of the National Academy of Sciences of the United States of America, 93, 1259-1264.
http://dx.doi.org/10.1073/pnas.93.3.1259
[27] Putsep, K., Branden, C.I., Boman, H.G. and Nomark, S. (1999) Antibacterial Peptide from H. pylori. Nature, 398, 671-672.
http://dx.doi.org/10.1038/19439
[28] Meichers, K., Weitznegger, T., Steinhilber, W., Sachs, G. and Schäfer, K.P. (1995) A Novel P Type ATPase Cloned from Helicobacter pylori. Gastroenterology, 108, A165.
http://dx.doi.org/10.1016/0016-5085(95)23322-9
[29] Moran, A.P. (1996) The Role of Lipopolysaccharide in Helicobacter pylori Pathogenesis. Alimentary Pharmacology & Therapeutics, 10, 39-50.
[30] Censini, S., Lange, C., Xiang, Z.Y., Crabtree, J.E., Ghiara, P., Borodovsky, M., Rappuoli, R. and Covacci, A. (1996) Cag, a Pathogenicity Island of Helicobacter pylori, Encodes Type I-Specific and Disease-Associated Virulence Factors. Proceedings of the National Academy of Sciences of the United States of America, 93, 14648-14653.
http://dx.doi.org/10.1073/pnas.93.25.14648
[31] Graham, D.Y. and Yamaoka, Y. (2000) Disease-Specific Helicobacter pylori Virulence Factors: The Unfulfilled Promise. Helicobacter, 5, S3-S9, Discussion S27-S31.
[32] Wu, A., Crabtree, J., Bernstein, L., Hawtin, P., Cokbum, M., Sosnowska, D. and Forman, D. (2001) Role of Helicobacter pylori Cag A+ Strains and Risk of Adenocarcinoma of the Stomach and Esophagus. Gastroenterology, 120, A14.
http://dx.doi.org/10.1016/S0016-5085(08)80070-4
[33] Cover, T.L. (1996) The Vacuolating Cytotoxin of Helicobacter pylori. Molecular Microbiology, 20, 241-246.
http://dx.doi.org/10.1111/j.1365-2958.1996.tb02612.x
[34] Peek Jr., R.M., Thompson, S.A., Donahue, J.P., Tham, K.T., Atherton, J.C., Blaser, M.J. and Miller, G.G. (1998) Adherence to Gastric Epithelial Cells Induces Expression of a Helicobacter pylori gene, IceA that Is Associated with Clinical Outcome. Proceedings of the Association of American Physicians, 110, 531-544.
[35] Go, M.F. and Crowe, S.E. (2000) Virulence and Pathogenicity of Helicobacter pylori. Gastroenterology Clinics of North America, 29, 649-670.
http://dx.doi.org/10.1016/S0889-8553(05)70136-9
[36] Vorobjova, T., Maaroos, H.I., Sipponen, P., Villako, K. and Uibo, R. (2001) Apoptosis in Different Compartments of Antrum and Corpus Mucosa in Chronic Helicobacter pylori Gastritis. An 18-Year Followup Study. Scandinavian Journal of Gastroenterology, 36, 136-143.
http://dx.doi.org/10.1080/003655201750065870
[37] Fennerty, M.B., Lieberman, D.A., Vakil, N., Magaret, N., Faigel, D.O. and Helfand, M. (1999) Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting. JAMA Internal Medicine, 159, 1562-1566.
http://dx.doi.org/10.1001/archinte.159.14.1562
[38] Iovene, M.R., Romano, M., Pilloni, A.P., Giordano, B., Montella, F., Caliendo, S. and Tufano, M.A. (1999) Prevalence of Antimicrobial Resistance in Eighty Clinical Isolates of Helicobacter pylori. Chemotherapy, 45, 8-14.
http://dx.doi.org/10.1159/000007159
[39] Ling, T.K., Cheng, A.F., Sung, J.J., Yiu, P.Y. and Chung, S.S. (1996) An Increase in Helicobacter pylori Strains Resistant to Metronidazole: A Five Year Study. Helicobacter, 1, 57-61.
http://dx.doi.org/10.1111/j.1523-5378.1996.tb00009.x
[40] Sunwoo, H.H. and Sim, J.S. (2003) IgY Technology for Human Health: Antimicrobial Activities of IgY Preparations against Foodborne Pathogens. The 225th ACS National Meeting, New Orleans, 23-27 March 2003.
http://oasys2.confex.com/acs/225nm/techprogram/P581665.HTM
[41] Hatta, H., Tsuda, K., Akachi, S., Kim, M. and Yamamoto, T. (1993) Productivity and Some Properties of Egg Yolk Antibody (IgY) against Human Rotavirus Compared with Rabbit IgG. Bioscience, Biotechnology, and Biochemistry, 57, 450-454.
http://dx.doi.org/10.1271/bbb.57.450
[42] Sun, S., Mo, W., Ji, Y. and Lius, S. (2001) Preparation and Mass Spectrometric Study of Egg Yolk Antibody (IgY) against Rabies Virus. Rapid Communications in Mass Spectrometry, 15, 708-712.
http://dx.doi.org/10.1002/rcm.271
[43] Woolley, J.A. and Landon, J. (1995) Comparison of Antibody Production to Human Interlukin-6 (IL-6) by Sheep and Chickens. Journal of Immunological Methods, 178, 253-265.
http://dx.doi.org/10.1016/0022-1759(94)00263-V
[44] Shimizu, M., Nagashima, H., Sano, K., Hashimoto, K., Ozeki, M. and Tsuda, K. (1992) Molecular Stability of Chicken and Rabbit Immunoglobulin G. Bioscience, Biotechnology, and Biochemistry, 56, 270-274.
http://dx.doi.org/10.1271/bbb.56.270
[45] Campbell, R.D., Dodds, A.W. and Porter, R.R. (1980) The Binding of Human Complement Component C4 to Antibody-Antigen Aggregates. Biochemical Journal, 189, 67-80.
[46] Fischer, M. and Hlinak, A. (2000) The Lack of Binding Ability of Staphylococcal Protein A and Streptococcal Protein G to Egg Yolk Immunoglobulins of Different Fowl Species. Berliner und Münchener tierärztliche Wochenschrift, 113, 94-96.
[47] Larsson, A., Karlsson-Parra, A. and Sjoquist, J. (1991) Use of Chicken Antibodies in Enzyme Immunoassays to Avoid Interferences by Rheumatoid Factors. Clinical Chemistry, 37, 411-414.
[48] Rubinstein, E., Kouns, W.C., Jennings, L.K., Boucheix, C. and Carroll, R.C. (1991) Interaction of two GPIIb/IIa Monoclonal Antibodies with Platlet Fc Receptor (FcγRII). British Journal of Haematology, 78, 80-86.
http://dx.doi.org/10.1111/j.1365-2141.1991.tb04386.x
[49] Narat, M. (2003) Production of Antibodies in Chickens. Food Technology and Biotechnology, 41, 259-267.
[50] Zeidler, G. (1998) Eggs Vital to Human and Animal Medicine. World’s Poultry, 14, 33-34.
[51] Chen, J.P. and Chang, M.C. (2003) Effect of Anti-Helicobacter pylori Urease Antibody (IgY) as a Food Ingredient on the Decrease of H. pylori in the Stomach of Humans Infected with H. pylori. Taiwanese Journal of Agricultural Chemistry and Food Science, 41, 408-414.
[52] Chandan, R.C. (1999) Enhancing Market Value of Milk by Adding Cultures. Journal of Dairy Science, 82, 2245-2256.
http://dx.doi.org/10.3168/jds.S0022-0302(99)75472-X
[53] Yamane, T., Saito, Y., Takizawa, S., Goshima, H., Kodama, Y., Horie, N. and Kim, M. (2003) Development of Anti-Helicobacter pylori Urease IgY and Its Application for Food Product. Food Processing and Ingredients, 38, 70. (in Japanese)
[54] Chang, Y., Min, S., Kim, K., Han, Y. and Lee, J. (2003) Delta (13)C-Urea Breath Test Value Is a Useful Indicator for Helicobacter pylori Eradication in Patients with Functional Dyspepsia. Journal of Gastroenterology and Hepatology, 6, 726-731.
http://dx.doi.org/10.1046/j.1440-1746.2003.03049.x
[55] Siriya, P., Chu, C., Chen, M., Lo, C., Huang, S. and Lien, T. (2013) Extraction and Purification of Anti-Helicobacter pylori IgY. Journal of Agricultural Science, 5, 132-138.
[56] Chiozzi, V., Mazzini, G., Oldani, A., Sciullo, A., Ventura, U., Romano, M., Boquet, P. and Ricci, V. (2009) Relationship between VacA Toxin and Ammonia in Helicobacter pylori-Induced Apoptosis in Human Gastric Epithelial Cells. Journal of Physiology and Pharmacology, 60, 23-30.
[57] Palframan, S.L., Kwok, T. and Gabriel, K. (2012) Vacuolating Cytotoxin A (VacA), a Key Toxin for Helicobacter pylori Pathogenesis. Frontiers in Cellular and Infection Microbiology, 2, 92.
http://dx.doi.org/10.3389/fcimb.2012.00092
[58] Fujikawa, A., Shirasaka, D., Yamamoto, S., Ota, H., Yahiro, K., Fukuda, M., Shintani, T., Wada, A., Aoyama, N., Hirayama, T., Fukamachi, H. and Noda, M. (2003) Mice Deficient in Protein Tyrosine Phosphatase Receptor Type Z Are Resistant to Gastric Ulcer Induced by VacA of Helicobacter pylori. Nature Genetics, 33, 375-381.
http://dx.doi.org/10.1038/ng1112
[59] Yamashita, Y., et al. (2010) Egg Yolk Antibodies Suppress H. pylori Infection and Gastritis. European Helicobacter Study Group. XXIII International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer, Rotterdam, 16-18 September 2010, 339.
[60] Zhou, X., Guo, L.Y., Yang, Z.B. and Chen, X.P. (2010) Protective Effects of Sucralfate on Anti-H. pylori VacA IgY in Vivo and in Vitro. African Journal of Microbiology Research, 4, 1091-1099.

  
comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.